The Boom of GLP-1 Products and the Need for Reliable CDMOs

GLP-1 receptor agonists, such as Tirzepatide, Semaglutide, and the emerging small-molecule drug Orforglipron, have revolutionized the treatment of metabolic diseases and obesity. As demand skyrockets, pharmaceutical companies face immense pressure to scale up production efficiently. Whether you are developing peptide-based injectables or oral small-molecule formulations, selecting a specialized CDMO for GLP-1 products is critical for commercial success.

Critical Capabilities for GLP-1 Manufacturing

Peptide Synthesis and Chemical Synthesis(API)

GLP-1 drugs include both complex peptides and small molecules. Your CDMO must have mature, optimized processes for both. For peptides like Semaglutide, experience in solid-phase peptide synthesis is required. For small molecules like Orforglipron, your partner must possess strong chemical synthesis capabilities and kilogram-level API production capacity to ensure high yield and purity.

Advanced Formulation Technologies (Injectables & Oral Solid Dosage)

Most peptide GLP-1 products are injectables, requiring GMP-standard workshops for sterile filling and lyophilization. However, for small-molecule GLP-1 products like Orforglipron, oral solid dosage (OSD) manufacturing capabilities are equally important.

GMP Compliance and Quality Assurance

Biological preparations and chemical APIs require rigorous quality control. The CDMO should utilize advanced analytical methods to ensure product stability, sterility, and compliance with international pharmacopoeia standards (USP, EP, BP).

Why CHU Pharma Stands Out in GLP-1 CDMO Services

CHU Pharma has mastered mature production processes for mainstream GLP-1 products. We produce biological products (like Tirzepatide and Semaglutide injections) in standardized GMP workshops with an annual production capacity exceeding 1 billion pieces.

Moreover, we have a dedicated kilogram-level API workshop, which is perfectly suited for the chemical synthesis of small-molecule GLP-1 products like Orforglipron. Our dedicated international registration team provides a true one-stop solution, covering everything from technical parameter docking to post-order quality follow-up.

Conclusion

Choosing a CDMO for GLP-1 products requires a partner with proven expertise in both peptide and small-molecule synthesis, sterile manufacturing capabilities, and strong regulatory support. CHU Pharma combines these strengths to help you accelerate your GLP-1 drug development. Contact us today to learn more about our CDMO capabilities.